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Improved prognosis in type 1 diabetic patients with nephropa-
thy: A prospective follow-up study.
Background. In early studies, a median survival time of 5
to 7 years from onset of diabetic nephropathy was observed.
Furthermore, end-stage renal disease (ESRD) was the main
cause of death. We prospectively assessed the impact of reno-
and cardiovascular protective treatment on prognosis in type 1
diabetic patients with diabetic nephropathy.
Methods. We prospectively followed 199 type 1 diabetic pa-
tients with diabetic nephropathy and 192 patients with normoal-
buminuria for 10 years. Aggressive antihypertensive treatment
was initiated in patients with diabetic nephropathy in mid 1980s,
whereas statins and aspirin were not prescribed routinely until
April 2002. The primary end point was cardiovascular mortality
and morbidity. Secondary end points were all-cause mortality
and ESRD.
Results. During follow-up, 79 patients (40%) with nephropa-
thy reached the primary end point versus 19 (10%) of normoal-
buminuric patients, log rank test P < 0.0001. Predictors of the
primary end point were: nephropathy (hazard ratio 3.26; 95%
confidence interval 1.89 to 5.62), previous event (3.19; 2.04 to
4.97), age (1.27; 1.04 to 1.55), and systolic blood pressure (1.13;
1.03 to 1.24). In the nephropathy group, 60 patients (30%) died;
hereof, 25 deaths (42%) were ascribed to cardiovascular causes
while 30 patients (50%) with nephropathy died with ESRD.
The estimate of median survival time from onset of diabetic
nephropathy was 21.7 years, SE 3.3 years.
Conclusion. The survival of patients with diabetic nephropa-
thy has improved most likely due to aggressive antihypertensive
treatment and improved glycaemic control.
Proteinuric patients with type 1 diabetes have an in-
creased mortality compared to the general population,
which is mainly due to end-stage renal disease (ESRD)
and cardiovascular disease [1]. The relative mortality
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from cardiovascular disease is 37-fold increased in these
patients [2]. In early studies of the natural course of dia-
betic nephropathy, a median survival time of 5 to 7 years
from onset of diabetic nephropathy was observed [3,
4]. At that time, ESRD was the cause of death in ap-
proximately 65% of patients [3]. Implementation of con-
ventional antihypertensive treatment with beta blockers,
diuretics, and vasodilators has improved the prognosis [5–
7]. The captopril collaborative study group demonstrated
a specific renoprotective effect of captopril in proteinuric
type 1 diabetic patients during 2.7 years of follow-up [8].
It is well known that lowering blood pressure re-
duces cardiovascular events [9, 10]. Epidemiologic stud-
ies clearly indicate that glycemic control is an important
cardiovascular risk factor [11, 12]. The Diabetes Con-
trol and Complications Trial (DCCT) suggested a ben-
eficial effect (borderline significance) of improved gly-
caemic control on cardiovascular events [13], and the
EDIC study found a reduction in intima media thickness
with intensive treatment [14].
In addition, lipid-lowering treatment with HMG-CoA-
reductase inhibitors reduces major cardiovascular events
in type 2 and type 1 diabetes (borderline significance)
[15]. Finally, antiplatelet treatment with low-dose aspirin
has been demonstrated to reduce cardiovascular risk in
diabetic patients [16].
In our prospective observational study lasting 10 years,
we assessed the impact of reno- and cardiovascular pro-
tective treatment on prognosis and cardiovascular mor-
bidity and mortality in patients with and with out diabetic
nephropathy.
METHODS
Patients and study design
In 1993, we examined the records of all albuminuric
patients attending the outpatient clinic at Steno Diabetes
Center who had type 1 diabetes and diabetic nephropa-
thy and had their glomerular filtration rate measured
the same year. A total of 242 Caucasian patients above
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18 years of age were identified and invited to participate in
the study—199 patients accepted and were enrolled in the
study [17, 18]. Diabetic nephropathy was diagnosed by
the following criteria: persistent albuminuria ≥300 mg/24
h in 2 of 3 consecutive 24-hour urine collections, pres-
ence of retinopathy, and no evidence of other renal or
urinary tract disease [6]. As control subjects we recruited
192 patients with longstanding type 1 diabetes and persis-
tent normoalbuminuria (urinary albumin excretion rate
<30 mg/24 h). The 2 groups were matched for sex, age,
and duration of diabetes.
In a prospective observational study patients were fol-
lowed until December 31 2003 or until death (N = 76) or
emigration (N = 3).
During follow-up, arterial hypertension was defined
and treated according to the World Health Organization’s
criteria (≥160/95 mm Hg) [19]. After the publication of
the captopril collaborative study in 1993 [8], inhibitors of
the angiotensin-converting enzyme have been advocated
as the initial step in the treatment of diabetic nephropa-
thy in type 1 diabetic patients. Statins and low-dose
aspirin were prescribed routinely to patients with dia-
betic nephropathy after new guidelines at Steno Diabetes
Center in April 2002.
The study was approved by the local ethics committee
and all patients gave their informed consent.
Baseline clinical and laboratory investigations
Investigations were performed in the morning after an
overnight fast. No antihypertensive medication was ever
prescribed in 24% of patients with nephropathy and 88%
of the normoalbuminuric patients. All of the remaining
patients were asked to stop their antihypertensive and
diuretic treatment 8 days before the examination. Not all
patients, however, complied and, thus, 34% and 4% of pa-
tients in the nephropathy and normoalbuminuria group,
respectively, had taken antihypertensive medication at
the day of the baseline examination.
Arterial blood pressure was measured twice with an
appropriate cuff size following at least 10 minutes rest
in supine position. Urinary albumin concentration was
measured by an enzyme immunoassay [20] from 24-hour
urine collections. Serum creatinine concentration was as-
sessed by a kinetic Jaffe´ method. GFR was measured in
patients with diabetic nephropathy after a single injection
of 3.7 MBq 51Cr-EDTA by determination of radioactiv-
ity in venous blood samples taken 180, 200, 220, and 240
minutes after the injection [21].
Diabetic retinopathy was assessed in all patients by fun-
dus photography after pupillary dilatation and graded as
nil, simplex, or proliferative retinopathy. Patients were
interviewed using the WHO cardiovascular question-
naire. Smoking was defined as persons smoking 1 or more
cigarettes/cigars/pipes a day, all others were classified as
nonsmokers.
End points
The primary end point was a composite cardiovascular
end point of cardiovascular death, history of nonfatal my-
ocardial infarction, percutanous coronary intervention
(PCI), coronary artery bypass grafting (CABG), nonfatal
stroke, amputation as a result of ischaemia, and vascular
surgery for peripheral atherosclerotic disease (PAD). The
secondary end points were all-cause mortality, cardiovas-
cular mortality, and death due to ESRD. Cardiovascular
death was classified as all deaths for which an unequivocal
noncardiovascular cause was not established [22].
All patients were traced in the national register in Jan-
uary 2004. If a subject had died before December 31, 2003,
the death certificate was obtained and the cause of death
was adjudicated by 2 masked observers. If the patient was
kidney transplanted, on dialysis, or the serum creatinine
concentration measured within a year before death was
≥500 lmol/L, the cause of death was coded as ESRD in
order to make comparison possible with data from the
literature [3, 4, 7, 23].
Information regarding the primary end point was ob-
tained from the WHO questionnaire and confirmed in
the patient files.
Follow-up examination
Follow-up examinations were carried out in 2003.
Of the 315 patients alive in 2003, 274 (87%) partici-
pated in the follow-up examination here of 121 patients
with nephropathy and 153 patients with normoalbumin-
uria.
All patients in the follow-up examination answered
to an extended WHO questionnaire about history of is-
chemic heart disease (IHD), stroke, amputation, claudi-
catio intermittens, dialysis, and renal transplantation.
To evaluate the prevalence of IHD at the follow-up
examination the WHO questionnaire was used together
with a resting 12-lead electrocardiogram (ECG). The
ECG was subsequently coded independently by 2 trained
observers, who were masked to the clinical status of the
patients, using the Minnesota Rating Scale [24]. IHD was
diagnosed if the ECG showed signs of probable myocar-
dial infarction (Minnesota code 1.1–2) or possible my-
ocardial ischemia (Minnesota Rating Scale 1.3, 4.1–4, 5.1–
3, and 7. 1).
Patients without history of IHD who were capable of
sitting on an exercise bike all performed an exercise ECG.
The test was carried out in accordance to guidelines from
the Danish Society of Cardiology [25]. Test results were
analyzed by a masked cardiologist (PRH) and classified
into pathologic test, normal test, or inconclusive test.
The test was defined as pathologic if the ECG showed
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exercise-induced ST-depression ≥2 mm, ventricular ar-
rhythmia during exercise, or development of left branch
bundle block. The test was considered inconclusive if the
patient failed to reach 85% of the calculated theoretical
maximum heart rate (220-patient age), and the ECG was
without pathologic findings.
In patients without lower limb amputation, PAD was
evaluated by measurement of the systolic blood pressure
in the big toe by a strain gauge technique [26]. Severe
PAD was considered evident in patients with a history of
amputation due to ischemia, of claudicatio intermittens,
or a systolic blood pressure in the big toe ≤30 mm Hg
[27].
Statistical analysis
At baseline, urinary albumin excretion rate, triglyc-
erides, and serum creatinine were non-normally
distributed and, therefore, log transformed before
analysis and given as medians (range). All other values
are given as mean ± SD. For normally distributed
variables, comparison between groups was performed
by an unpaired Student t test or analysis of variance
(ANOVA). In non-normally distributed continuous
variables, a Mann-Whitney U test or Kruskal-Wallis test
were used for comparison between groups. A chi-square
test was used to compare noncontinuous variables.
The primary end point and all-cause mortality were an-
alyzed with event curves for time to the first event based
on Kaplan-Meier analysis, and groups were compared by
log rank test.
To make an estimation of survival from onset of dia-
betic nephropathy, patients were left truncated and con-
tributed for the time corresponding to the duration of
nephropathy at baseline. For example, a patient with
4 years of nephropathy at baseline was not considered at
risk of dying in the first 4 years from onset of nephropa-
thy. To compare our data with earlier studies of prog-
nosis in patients with diabetic nephropathy we made a
secondary analysis combining death and renal death (pa-
tients alive treated with dialysis or renal transplantation)
because these patients in the past would have died from
ESRD.
In the analysis of predictors of the primary end point
and all-cause mortality, Cox proportional hazards analy-
ses were used. These were based on stepwise backward
selection of baseline data including gender, presence of
nephropathy, 10 years increase in age, history of cardio-
vascular disease, smoking, 10 mm Hg increase in systolic
blood pressure, HbA1c, and serum cholesterol. Results
are described as hazard ratios with 95% confidence inter-
vals.
Cardiovascular death and death from other causes in
the 2 groups could not be validly compared because of
too few events in the normoalbuminuric group.
Two-tailed P values ≤ 0.05 were considered significant.
All calculations were made with SPSS version 12.0 or
Stata Statistical Software release 8.0 (Chicago, IL, USA).
RESULTS
Baseline characteristics are shown in Table 1.
The median follow-up until death or last visit was 10.1
years (0–10.3).
At the end of follow-up, 43% of patients with nor-
moalbuminuria and all patients with nephropathy, except
2 who were in dialysis, were receiving antihypertensive
treatment predominantly with RAS blockade (Table 2).
Nonfatal and fatal cardiovascular disease during
follow-up
During the follow-up, 79 patients (40%) with
nephropathy reached the combined primary end point
versus 19 patients (10%) with normoalbuminuria, log
rank test P < 0.0001 (Fig. 1). The 79 nephropathic pa-
tients affected with the primary end point experienced
a total of 107 events, including 25 deaths from cardio-
vascular causes, 23 coronary interventions or myocardial
infarctions, 24 strokes, and 35 lower limb amputations or
peripheral bypass procedures.
Cox multiple regression analysis identified the fol-
lowing significant predictors of the primary end point:
nephropathy (hazard ratio 3.26; 95% confidence interval
1.89 to 5.62, P < 0.0001), history of cardiovascular event
(3.19; 2.04 to 4.97, P < 0.0001), 10-year increase of age
(1.27; 1.04 to 1.55, P = 0.02), and 10 mm Hg increase
in systolic blood pressure (1.13; 1.03 to 1.24, P = 0.009).
Sex, smoking, HbA1c, and total cholesterol were not sig-
nificant predictors of the primary end point in the final
model. However, if patients with a history of cardiovas-
cular event on baseline were excluded from the analysis,
HbA1c came out as an independent predictor of the pri-
mary end point (hazard ratio 1.16; 95% CI 1.01 to 1.33,
P = 0.038) together with nephropathy (3.15; 1.80 to 5.50,
P < 0.0001), 10-year increase in age (1.41; 1.15 to 1.73,
P = 0.001), and a 10 mm Hg increase in systolic blood
pressure (1.20; 1.01 to 1.31, P < 0.0001).
In Table 3, cardiovascular risk factors are shown in
patients who survived the follow-up period and partic-
ipated in the follow-up examination (N = 274). The
table shows that the survivors had a significant reduc-
tion in HbA1c during follow-up. High-density lipoprotein
(HDL) cholesterol levels increased while total choles-
terol, low-density lipoprotein (LDL) cholesterol, and
triglycerides was reduced. As expected, creatinine levels
increased during follow-up, whereas UAER was reduced
together with blood pressure. The frequency of smoking
was reduced in both patients with nephropathy and pa-
tients with normoalbuminuria.
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Table 1. Baseline data in 391 type 1 diabetic patients with and without diabetic nephropathy
Patients with
normoalbuminuria Patients with diabetic
at baseline nephropathy at baseline
(N = 192) (N = 199) P value
Sex (M/F) 118/74 122/77 ns
Age years 43 ± 10 41 ± 9 ns
Duration of diabetes years 27 ± 8 28 ± 8 ns
BMI kg/m2 23.6 ± 2.5 24.0 ± 3.3 ns
HbA1c% 8.5 ± 1.1 9.5 ± 1.5 <0.001
Glomerular filtration rate mL/min/1.73m2 74 ± 34 –
Urinary albumin excretion rate mg/24ha 8 (1–30) 796 (16–14565) –
S-creatinine lmol/L 76 (40–116) 103 (54–684) <0.001
Systolic blood pressure mm Hg 132 ± 18 151 ± 23 <0.001
Diastolic blood pressure mm Hg 76 ± 10 86 ± 13 <0.001
Smoking 43% 50% ns
History of stroke 2 (1) 14 (7) <0.001
History of myocardial infarction 2 (1) 10 (5) <0.001
History of stroke/myocardial infarction 4 (2) 21 (11) <0.001
Retinopathy (nil/simplex/proliferative) 67/106/19 0/62/137 <0.001
Total cholesterol mmol/L 4.8 ± 1.0 5.6 ± 1.2 <0.001
HDL-cholesterol mmol/L 1.56 ± 0.5 1.46 ± 0.5 <0.001
LDL-cholesterol mmol/L 2.82 ± 0.9 3.54 ± 1.1 <0.001
Triglycerides mmol/L 0.77 (0.3–3.1) 1.22 (0.3–9.9) <0.001
Data are N (%), mean ± SD, or medians (range).
aSome patients with previously persistent albuminuria receiving antihypertensive medication had a UAE <300 mg/24 h. Values are the mean of 3 24-hour urine
collections.
Table 2. Reno- and cardioprotective treatment at the beginning and in the end of study
Beginning of study End of study
Variable Normoalbuminuria Nephropathy Normoalbuminuria Nephropathy
(N = 192) (N = 199) (N = 153) (N = 121)
No. of patients treated with antihypertensive drugs (%) 27 (14) 153 (77) 66 (43) 119 (98)
Number of drugs—no. of patients (%)
0 165 (86) 45 (23) 87 (57) 2 (2)
1 19 (10) 38 (19) 24 (16) 16 (13)
2 6 (3) 63 (32) 26 (17) 52 (43)
3 2 (1) 42 (21) 14 (9) 42 (35)
4 0 10 (5) 2 (1) 9 (7)
ACE inhibitora 9 (5) 106 (53) 46 (30) 76 (63)
Angiotensin II-receptor antagonist 0 0 20 (13) 26 (22)
Diuretic 15 (8) 129 (65) 36 (24) 92 (76)
Calcium channel blocker 6 (3) 44 (22) 17 (11) 44 (36)
Beta-blocker 3 (2) 28 (14) 5 (3) 22 (18)
Statin 0 0 37 (24) 61 (50)
Aspirin 4 (2) 21 (11) 60 (33) 79 (65)
Data are N (%).
aACE denotes angiotensin-converting enzyme.
All-cause mortality and ESRD during follow-up
Of the 199 patients with nephropathy, 60 patients
(30%) died during follow-up versus 16 patients (8%) of
the 192 patients with normoalbuminuria, log rank test
P < 0.0001. In patients with nephropathy, 25 deaths
(42%) were ascribed to cardiovascular causes versus 7
(38%) in normoalbuminuric patients. ESRD was the
cause of death in 30 patients (50%) with overt nephropa-
thy. Among the 139 patients with nephropathy alive at
the end of the study, 11 had a renal transplantation and 9
were on dialysis. Thus, in total, 50 type 1 diabetic patients
(25%) with nephropathy reached ESRD during 10 years
of follow-up.
Figure 3 shows the left truncated survival curve for 199
patients from onset of diabetic nephropathy. The estimate
of median survival time in our study is 21.7 years, standard
error 3.3 years.
In order to make our data comparable with historic
data [4, 7, 23, 28], we made a secondary analysis combin-
ing death and renal death (patients alive and treated with
dialysis or renal transplantation because these patients in
the past would have died from ESRD). In this analysis,
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Fig. 1. The cumulative incidence of fatal and nonfatal cardiovascu-
lar disease in 391 type 1 diabetic patients with and without diabetic
nephropathy.
the median time until ESRD or death was 18.3 years, SE
2.1 years. In Figure 4 our survival estimate is compared
with historic data [4, 7, 23, 28].
Ischemic heart disease at follow-up
At the follow-up examination the prevalence of IHD
was evaluated by WHO questionnaire and Minnesota
coded resting ECGs in all patients. Furthermore, of
the 274 patients in the follow-up examination, 215 per-
formed an exercise ECG, hereof 82 with nephropathy
and 133 with normoalbuminuria. Thus, 39 patients with
nephropathy and 20 patients with normoalbuminuria did
not perform an exercise test due to history of myocardial
infarction or coronary intervention, amputation, stroke,
or dialysis.
Among patients with diabetic nephropathy, 55 of 82
(67%) had a conclusive test, 5 of which were pathologic.
In the normoalbuminuric group, 120 of 133 (90%) were
conclusive hereof 10 positive for IHD.
In total, 40 patients of 121 (33%) with nephropathy
participating in the follow-up examination had signs or
symptoms of IHD evaluated from resting ECG, WHO-
questionnaire, and exercise ECG versus 23 of 153 (15%)
patients with normoalbuminuria, P < 0.0001.
Peripheral arterial disease at follow-up
Amputations due to ischaemia or peripheral bypass
surgery were performed in 19 patients with diabetic
nephropathy and in 1 patient with normoalbuminuria. In
addition, 24 and 14 patients with diabetic nephropathy or
normoalbuminuria, respectively, reported symptoms of
claudicatio intermittens. Finally, in patients free of symp-
toms, a blood pressure ≤30 mm Hg on the big toe was
found in 4 patients with diabetic nephropathy and 2 with
normoalbuminuria. Thus, a total of 47 patients with dia-
betic nephropathy had signs or symptoms of PAD versus
17 patients with normoalbuminuria, P < 0.0001.
After 10 years of follow-up, only 58 patients (32%) with
diabetic nephropathy had no signs or symptoms of CVD
or ESRD. In the normoalbuminuric group, 120 patients
(78%) of patients remained free of CVD after 37 years
of diabetes duration (Fig. 2).
DISCUSSION
Our prospective follow-up study shows that 40% of
patients with diabetic nephropathy reach a composite end
point of cardiovascular morbidity and mortality during 10
years of follow-up. Furthermore, an improved survival
was observed in patients with diabetic nephropathy with
an estimated median survival time of 21.7 years. In half of
the patients, ESRD was classified as the cause of death,
whereas 42% died from cardiovascular disease.
Our Cox analysis showed that in type 1 diabetes the
presence of diabetic nephropathy increased the relative
risk of major cardiovascular events to the same extent
as having a history of stroke or myocardial infarction.
In fact, having diabetic nephropathy is associated with a
large risk of cardiovascular disease, and in our study only
32% of patients with diabetic nephropathy were still alive
and without CVD after 10 years of follow-up. In contrast,
we found that the majority of patients in the normoalbu-
minuric group remained free of cardiovascular disease
after 37 years’ duration of diabetes.
Excess mortality in type 1 diabetic patients with overt
diabetic nephropathy has been reported by many stud-
ies [1, 4]. In early studies of the natural history of dia-
betic nephropathy at Steno Diabetes Center, a median
survival time from onset of diabetic nephropathy was 5
to 7 years [3, 4]. At that time, 66% of patients were dying
with uraemia and 19% to 23% from cardiovascular dis-
ease [4]. Today the incidence of diabetic nephropathy in
type 1 diabetic patients has decreased [29, 30]. A survey
from our clinic performed almost 10 years ago found the
estimated survival time from onset of diabetic nephropa-
thy to be 13.9 years (95% confidence interval 11.8 to 17.2
years) [7]. Because patients were not routinely treated
for ESRD with dialysis or renal transplantation until
the beginning of the 1990s we made a secondary anal-
ysis labelling patients who were alive but reached ESRD
(treated with dialysis or renal transplantation) as dead
at time of follow-up. In this analysis we found a median
survival time of 18.3 years. The improved survival in pa-
tients with nephropathy in our study could be influenced
by an improvement in several risk factors: glycemic con-
trol was improved during follow-up, but only from 9.3%
to 8.7% in HbA1c. Because the DCCT trial [13] only ob-
served a borderline effect on cardiovascular disease with
a much larger improvement in HbA1c (1.7% reduction
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Table 3. Cardiovascular risk factors in survivors who participated in the follow-up examination
Beginning of study End of study
Normoalbuminuria Nephropathy Normoalbuminuria Nephropathy
Variable (N = 153) (N = 121) P valuea (N = 153) P valueb (N = 121) P valuec
HbA1c% 8.5 ± 1.1 9.3 ± 1.4 <0.001 8.0 ± 1.0 <0.001 8.7 ± 1.2 <0.001
Total cholesterol mmol/L 4.8 ± 0.8 5.3 ± 1.2 <0.001 4.7 ± 1.0 <0.001 4.8 ± 0.9 <0.001
HDL-cholesterol mmol/L 1.56 ± 0.4 1.47 ± 0.6 <0.001 1.9 ± 0.5 0.032 1.78 ± 0.6 <0.001
LDL-cholesterol mmol/L 2.80 ± 0.9 3.29 ± 1.1 <0.001 2.48 ± 0.6 <0.001 2.41 ± 0.7 <0.001
Triglycerides mmol/L 0.8 (0.3–3) 1.2 (0.3–5) <0.001 1.0 (0.3–3) <0.001 1.44 (0.3–6) 0.007
Urinary albumin excretion rate mg/24hd 8 (1–29) 672 (35–5812) – 8 (2–334) 0.011 129 (3–3783) <0.001
S-creatinine lmol/L 76 (40–116) 118 (59–587) <0.001 86 (61–144) <0.001 169 (76–939) 0.001
Systolic blood pressure mm Hg 130 ± 17 145 ± 22 <0.001 136 ± 17 <0.001 140 ± 19 0.01
Diastolic blood pressure mm Hg 75 ± 10 84 ± 12 <0.001 72 ± 8 <0.001 74 ± 9 <0.001
Smoking % 37% 46% 0.13 35% 0.31 38% 0.03
Data are mean ± SD, or medians (range), or%.
aP values are for the differences between groups at the beginning of the study.
bP values are for differences between baseline and follow-up examination in patients with normoalbuminuria.
cP values are for differences between baseline and follow-up examination in patients with nephropathy.
dSome patients with previously persistent albuminuria receiving antihypertensive medication had a UAE <300 mg/24 h.
Patients with nephropathy 
N = 199
Patients with normoalbuminuria 
N = 192
Dead at follow-up 
N = 60
Dead at follow-up 
N = 16
Alive but lost to follow-up 
N = 18
Alive but lost to follow-up 
N = 23
Stroke 
N = 24 (20%)*
IHD 
N = 40 (33%)*
PAD 
N = 47 (39%)*
PAD 
N = 17 (11%)*
IHD 
N = 23 (15%)*
Stroke 
N = 5 (3%)*
Alive and no stroke, PAD, 
or IHD 
N = 58 (32%)*
Alive and no stroke, PAD, 
or IHD 
N = 120 (71%)*
Patients in follow-up examination 
N = 121
Patients in follow-up examination 
N = 153
Fig. 2. Flow chart on mortality and cardiovascular disease in 391 type 1 diabetic patients with nephropathy or normoalbuminuria after 10 years
of follow-up. Percentages are of patients not lost to follow-up. Some patients both suffered a stroke and had ischemic heart disease (IHD), or
peripheral arterial disease (PAD).
in the intensively treated group), it is not likely that the
improvement in glycemic control in our study could give
more than a small contribution to the improved prog-
nosis. Because low-dose aspirin and statins were not im-
plemented at Steno Diabetes Center before April 2002,
this can probably not explain the improved prognosis.
However, prognosis could be influenced by the reduction
in the frequency of smoking among patients. The most
marked reduction of risk factors observed in our patients
was in blood pressure, most likely as a consequence of the
intensified antihypertensive therapy implemented during
the follow-up period. We are thus convinced that the ma-
jor improvement in prognosis in patients with diabetic
nephropathy in our study is due to long-term aggressive
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tients (patients with overt diabetic nephropathy in our study were left
truncated and contributed from the time corresponding to duration of
overt diabetic nephropathy at the baseline examination).
antihypertensive treatment, with smaller contributions
from improvements in glycemic control and smoking
cessation.
Based on data from the Finnish Hospital Discharge
Register, a study of 5248 Finnish type 1 diabetic pa-
tients reported a 10-fold increase in relative risk for IHD,
stroke, or any CVD in type 1 diabetic patients hospital-
ized with a diagnosis of diabetic nephropathy as com-
pared to patients not discharged with this diagnosis [31].
After 24 years of diabetes duration, the cumulative in-
cidence of fatal and nonfatal CVD was 24% and 4%
in patients with and without the diagnosis of diabetic
nephropathy, respectively. Another study [32] found an
even higher prevalence of clinically diagnosed ischemic
heart disease: 32% in diabetic patients entering dialysis.
Our data are in accordance with a previous report from
Germany [33], which found a 10-year mortality of 31.1%
in patients with proteinuria above 500 mg/L.
In the present study, diabetic nephropathy was diag-
nosed based on clinical definitions in all type 1 diabetic
patients attending the outpatient clinic at our hospital,
and not exclusively the subset of more severely affected
patients requiring in-patient admission as in the Finnish
study, which may explain the lower rate of CVD in our
study. Accordingly at baseline, after 27 to 28 years of
type 1 diabetes, the prevalence of major nonfatal CVD
was 11% and 2% in our cohorts with and without di-
abetic nephropathy, respectively. Furthermore, in our
study, prevalence estimates of nonfatal CVD are applied
at baseline, whereas figures from the Finnish study are
cumulative incidences of fatal and nonfatal events.
Thus, differences in design and case/control definitions
are most likely to account for the absolute differences
between the 2 studies. Both studies, however, confirm and
extend earlier observations of a significantly increased
incidence of IHD and CVD in type 1 diabetic patients
with nephropathy [34].
In our study, 50% of deaths in patients with diabetic
nephropathy were due to ESRD and 42% to cardiovas-
cular disease.
Type 1 diabetic patients have a high prevalence of silent
coronary atheromatosis [35], and several studies have
found that symptom-free patients with diabetes more
common have abnormalities in exercise ECG than nondi-
abetics [36].The high prevalence of silent IHD may partly
be caused by cardiac autonomic neuropathy [37]. In our
study, all patients capable of performing an exercise ECG
were asked to do so. In our laboratory, patients with nor-
moalbuminuria had no difficulties performing the exer-
cise test, but in patients with diabetic nephropathy the
test was not useful for excluding ischemic heart disease
because 1 out of 3 patients could not exercise sufficiently
to obtain a conclusive test result. Patients with diabetic
nephropathy are at extremely high risk of IHD and, there-
fore, it may be necessary to systematically screen for
IHD using alternative techniques (i.e., myocardial per-
fusion techniques, magnetic resonance scanning, or even
coronary angiography). The prognosis in these high-risk
patients may further improve if significant but clinically
silent IHD was detected and treated aggressively (e.g.,
with cardioprotective drugs and perhaps even with my-
ocardial revascularization procedures). Whether such an
approach will translate into improved prognosis for pa-
tients with diabetic nephropathy remains to be clarified.
CONCLUSION
We have confirmed and exceeded the major improve-
ment in survival in type 1 diabetic patients with diabetic
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nephropathy. The improved prognosis in our cohort of
patients with diabetic nephropathy is mostly due to ag-
gressive long-term antihypertensive treatment in addi-
tion to improved glycemic control and smoking cessation
because treatment with statins and low-dose aspirin were
not implemented until the near end of follow-up. Dia-
betic nephropathy, however, remains a major risk factor
for cardiovascular morbidity and mortality in type 1 dia-
betic patients. Prognosis might improve even further with
better glycemic control and treatment with statins and
low-dose aspirin.
Consequently, our study indicates that the future focus
of patient care must be multifactorial treatment aiming at
postponing ESRD and reducing cardiovascular disease.
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